Identification of New Inhibitors of Trypanosoma cruzi Enzymes

On going
Start date
Start stage
Chagas disease
Research areas

In an effort to develop novel drugs against Chagas disease, Dr. Artur Cordeiro at the Brazilian Biosciences National Laboratory (LNBio) has identified chemical scaffolds that have shown activity against two promising targets and efficacy against the parasite’s intracellular form. In order to identify additional inhibitors or novel chemical scaffolds with activity against both Trypanosoma cruzi enzymes, Dr. Cordeiro will be working with Novartis as part of their Facilitated Access to Screening Technologies (FAST) Lab program to screen several of Novartis’ proprietary compounds against these two targets to identify tool compounds for structure-based drug discovery.